Global Financial Markets

Regeneron to Report First Quarter 2021 Monetary and Working Outcomes and Host Convention Name and Webcast on Might 6, 2021

TARRYTOWN, N.Y., April 6, 2021 /PRNewswire/ — Regeneron Prescription drugs, Inc. (NASDAQ: REGN) in the present day introduced that it’ll report its first quarter 2021 monetary and working outcomes on Thursday, Might 6, 2021, earlier than the U.S. monetary markets open. The Firm will host a convention name and simultaneous webcast at 8:30 AM Jap Time that day.

Convention Name Data
To entry this name, dial (888) 660-6127 (U.S.) or (973) 890-8355 (Worldwide), convention ID 7794757. A hyperlink to the webcast could also be accessed from the ‘Traders and Media’ web page of Regeneron’s web site at http://investor.regeneron.com/occasions.cfm. A replay of the convention name and webcast will probably be archived on the Firm’s web site for a minimum of 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a number one biotechnology firm that invents life-transforming medicines for folks with critical illnesses. Based and led for over 30 years by physician-scientists, our distinctive capability to repeatedly and persistently translate science into drugs has led to 9 FDA-approved therapies and quite a few product candidates in growth, virtually all of which had been homegrown in our laboratories. Our medicines and pipeline are designed to assist sufferers with eye illnesses, allergic and inflammatory illnesses, most cancers, cardiovascular and metabolic illnesses, ache, infectious illnesses and uncommon illnesses.

Regeneron is accelerating and bettering the standard drug growth course of via our proprietary VelociSuite® applied sciences, akin to VelocImmune®, which makes use of distinctive genetically humanized mice to provide optimized absolutely human antibodies and bispecific antibodies, and thru bold analysis initiatives such because the Regeneron Genetics Middle, which is conducting one of many largest genetics sequencing efforts on this planet.

For added details about the corporate, please go to www.regeneron.com or observe @Regeneron on Twitter.

Contact Data:
Investor Relations
Justin Holko
914.847.7786
justin.holko@regeneron.com

Company Communications
Hala Mirza
914.847.3422
hala.mirza@regeneron.com

Cision

Cision

View unique content material:http://www.prnewswire.com/news-releases/regeneron-to-report-first-quarter-2021-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-6-2021-301263387.html

SOURCE Regeneron Prescription drugs

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button